16th EORTC – NCI – AACR Symposium – 'Molecular Targets and Cancer Therapeutics'
The 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics brings 2,000 international cancer experts together to present new data on leading-edge basic, translational and early clinical research.
12.30 hrs CET Thursday 30 September
Speakers and topics:
* Dr. Jacqueline Limpens: Study shows lycopene and vitamin E inhibits growth of prostate tumours in mice, underpinning epidemiological evidence. Phase II trial in patients now under way.
* Dr. Olivier Feron: A revolutionary approach to angiogenesis - exploiting tumour blood vessels to boost chemotherapy and radiotherapy instead of (or before) killing them. Successful mouse study leads to patient trial.
* Professor Eric Van Cutsem: International trial results shows way to measure success of centuximab (Erbitux). Randomised study now under way
Chairman: Professor Jaap Verweij (EORTC chairman of conference scientific committee) together with scientific committee co-chairmen Dr Janet Dancey (NCI) and Dr Eric K Rowinsky (AACR).
NB: any reports involving the topics outlined above are embargoed until the time and date of the news briefing.
Journalists wishing to dial in to the news briefing should contact Margaret Willson by Friday 25 September
Conference Press Officer
Conference media centre:
From 16.00 hrs CET Monday 27 September to 17.00 hrs CET Friday 1 October
Source: Eurekalert & othersLast reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.